APP and amyloidosis: Chen L et al. [192] demonstrated that prolonged administration of hyperoside drugs enhances spatial learning and memory abilities in APP/PS1 transgenic mice, reduces amyloid plaque deposition and tau phosphorylation, and mitigates neuroinflammation and oxidative stress in the brains of APP/PS1 mice by downregulating BACE1 and GSK3β levels, thereby attenuating the activation of microglia and astrocytes.